By Fred R. Hirsch, MD, PhD Posted: April 2018 Immunotherapy is a very encouraging development in the treatment of patients with lung cancer. At this phase of its refinement, we struggle […]
By Roy S. Herbst, MD, PhD The National Cancer Institute’s (NCI’s) Lung Cancer Specialized Programs of Research Excellence (SPORE) and their affiliates met June 21-22, 2017, to discuss current trends […]
By K. Michael Cummings, PhD, MPH, andGraham Warren, MD, PhD Posted: April 2018 On July 28, 2017, the U.S. Food and Drug Administration (FDA) announced a new emphasis in the […]
Posted: April 2018 In January 2018, the response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group—an international collaboration of cancer treatment, scientific, and imaging experts— published a new guideline on […]
By Jason N. Rosenbaum, MD, andDara L. Aisner, MD, PhD Posted: April 2018 Within the span of a few weeks, the U.S. Food and Drug Administration (FDA), the Center for […]
Tumors with high TMB responded well to combination in large patient population. By now the results of the phase III CheckMate-227 study are known by most. The primary endpoint of […]
The Heine Hansen Award recipient is IASLC Lung Cancer News Associate Editor Fabrice Barlesi, MD. His lecture will be “The Power of Multiple H.” “I’m unbelievably grateful to the ESMO […]
By Tiziana Vavalà, MD, andSilvia Novello, MD, PhD Posted: April 2018 Approximately 1.8 million new lung cancer cases worldwide are diagnosed annually, and 85% of these cases are NSCLC. Only […]
By C.A.I.R.O Journal Club Executive Board Posted: April 2018 In early February, the Critical Appraisal Initiative for Research in Oncology (C.A.I.R.O) Journal Club celebrated its fourth anniversary by hosting a […]
Posted: April 2018 Solange Peters, MD-PhD, PD-MER, runs the Thoracic Malignancies Program in the Department of Oncology at the University of Lausanne, Switzerland. Her main field of interest is new […]